Literature DB >> 11165043

Transcriptional activation of cathepsin D gene expression by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition.

F Wang1, I Samudio, S Safe.   

Abstract

17beta-estradiol (E2) induces cathepsin D gene expression in MCF-7 human breast cancer cells and this response is inhibited by aryl hydrocarbon receptor (AhR) agonists, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Analysis of the cathepsin D gene promoter initially identified a pentanucleotide GCGTG core dioxin responsive element (DRE) that blocked E2 action by inhibiting formation of a transcriptionally active estrogen receptor (ER)-Sp1 complex. A second functional downstream inhibitory DRE (iDRE2) (-130 to -126) has now been identified in the cathepsin D gene promoter and inhibition of E2-induced transactivation involves inhibitory AhR crosstalk with the E2-responsive adenovirus major late promoter element (MLPE) at -124 to -104 in the cathepsin D gene promoter. The MLPE site primarily binds USF1/USF2 and ERalpha, and gel mobility shift and DNA footprinting assays show that the AhR complex decreases binding of these transcription factors to the MLPE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165043     DOI: 10.1016/s0303-7207(00)00379-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  19 in total

1.  Aryl hydrocarbon receptor modulation of estrogen receptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140.

Authors:  Zeynep Madak-Erdogan; Benita S Katzenellenbogen
Journal:  Toxicol Sci       Date:  2011-11-09       Impact factor: 4.849

Review 2.  Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.

Authors:  Mark E Hahn; Lenka L Allan; David H Sherr
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

3.  Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Authors:  Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2014-12

Review 4.  Implication of environmental estrogens on breast cancer treatment and progression.

Authors:  Thomas L Gonzalez; James M Rae; Justin A Colacino
Journal:  Toxicology       Date:  2019-03-30       Impact factor: 4.221

Review 5.  Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor.

Authors:  Michael S Denison; Anatoly A Soshilov; Guochun He; Danica E DeGroot; Bin Zhao
Journal:  Toxicol Sci       Date:  2011-09-09       Impact factor: 4.849

6.  E2-mediated cathepsin D (CTSD) activation involves looping of distal enhancer elements.

Authors:  Nancy Bretschneider; Sara Kangaspeska; Martin Seifert; George Reid; Frank Gannon; Stefanie Denger
Journal:  Mol Oncol       Date:  2008-05-29       Impact factor: 6.603

7.  Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters.

Authors:  Shaimaa Ahmed; Eivind Valen; Albin Sandelin; Jason Matthews
Journal:  Toxicol Sci       Date:  2009-07-02       Impact factor: 4.849

Review 8.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

9.  Characterization of oligoadenylate synthetase-1 expression in rat mammary gland and prostate: effects of 17beta-estradiol on the regulation of OAS1g in both tissues.

Authors:  C J B Maia; S Socorro; F Schmitt; C R A Santos
Journal:  Mol Cell Biochem       Date:  2008-04-18       Impact factor: 3.396

Review 10.  The aryl hydrocarbon receptor complex and the control of gene expression.

Authors:  Timothy V Beischlag; J Luis Morales; Brett D Hollingshead; Gary H Perdew
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.